BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27642214)

  • 1. Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites.
    Tajima S; Koda K
    Dis Markers; 2016; 2016():2940496. PubMed ID: 27642214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma.
    van Pel DM; Pors J; Yuen E; Chan R; Kos Z; Hayes MM; Wang G
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):681-686. PubMed ID: 36227121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
    Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
    Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
    Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracytoplasmic lipid accumulation in apocrine carcinoma of the breast evaluated with adipophilin immunoreactivity: a possible link between apocrine carcinoma and lipid-rich carcinoma.
    Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Shiraiwa M; Nishida C; Morita T; Sato Y; Hayashi T; Kato A
    Am J Surg Pathol; 2011 Jun; 35(6):861-7. PubMed ID: 21566511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed pleomorphic lobular and apocrine carcinoma of the breast: A case report suggesting pathogenesis.
    Ishii A; Oishi T; Kakuda Y; Yasui H; Kawata T; Muramatsu K; Takahashi K; Sugino T
    Pathol Int; 2019 May; 69(5):288-293. PubMed ID: 30811750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
    Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
    Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual apocrine carcinoma with neuroendocrine differentiation: a cutaneous neoplasm may be analogous to neuroendocrine carcinoma with apocrine differentiation of breast.
    Li Y; Chen LL; Li B; Tian XY; Li Z
    Diagn Pathol; 2015 Jun; 10():64. PubMed ID: 26055980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
    Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
    Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma.
    Narendra S; Jenkins SM; Khoor A; Nassar A
    Ann Diagn Pathol; 2015 Apr; 19(2):64-9. PubMed ID: 25682191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
    Hoang LL; Tacha DE; Qi W; Yu C; Bremer RE; Chu J; Haas TS; Cheng L
    Arch Pathol Lab Med; 2014 Jul; 138(7):943-9. PubMed ID: 24978921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
    Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
    Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apocrine differentiation in invasive pleomorphic lobular carcinoma with in situ ductal and lobular apocrine carcinoma: case report.
    Kaya H; Aribal E; Yegen C
    Pathol Oncol Res; 2002; 8(2):151-2. PubMed ID: 12172583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
    Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
    Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations and Prognosis.
    Liu YL; Choi C; Lee SM; Zhong X; Hibshoosh H; Kalinsky K; Connolly EP
    Clin Breast Cancer; 2018 Apr; 18(2):114-120. PubMed ID: 28720418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
    Lionti S; La Rocca L; Nunnari CM; Barresi V
    Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
    D'Arcy C; Quinn CM
    J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid apocrine carcinoma of the skin: report of a rare adnexal neoplasm mimicking lobular breast carcinoma.
    Zelger BG; Stelzmueller I; Dunst KM; Zelger B
    J Cutan Pathol; 2008 Mar; 35(3):332-6. PubMed ID: 18251751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.